165 results on '"EOE"'
Search Results
2. Dupilumab for Eosinophilic Esophagitis With Severe Strictures (DESTRICT)
- Author
-
Regeneron Pharmaceuticals and Sanofi
- Published
- 2024
3. Contribution of T cell subsets to different food allergic diseases.
- Author
-
Hung, Lisa, Zientara, Brianna, and Berin, M. Cecilia
- Subjects
- *
T cells , *ALLERGIES , *FOOD allergy , *SYMPTOMS , *MILK allergy , *PEANUT allergy - Abstract
Summary Food allergies occur due to a lack of tolerance to the proteins found in foods. While IgE‐ and non‐IgE‐mediated food allergies have different clinical manifestations, epidemiology, pathophysiology, and management, they share dysregulated T cell responses. Recent studies have shed light on the contributions of different T cell subsets to the development and persistence of different food allergic diseases. This review discusses the role of T cells in both IgE‐ and non‐IgE‐mediated food allergies and considers the potential future investigations in this context. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis–Current Treatment and Monitoring.
- Author
-
de Bortoli, Nicola, Visaggi, Pierfrancesco, Penagini, Roberto, Annibale, Bruno, Baiano Svizzero, Federica, Barbara, Giovanni, Bartolo, Ottavia, Battaglia, Edda, Di Sabatino, Antonio, De Angelis, Paola, Docimo, Ludovico, Frazzoni, Marzio, Furnari, Manuele, Iori, Andrea, Iovino, Paola, Lenti, Marco Vincenzo, Marabotto, Elisa, Marasco, Giovanni, Mauro, Aurelio, and Oliva, Salvatore
- Abstract
The present document constitutes Part 2 of the EoETALY Consensus Statements guideline on the diagnosis and management of eosinophilic esophagitis (EoE) developed by experts in the field of EoE across Italy (i.e., EoETALY Consensus Group). Part 1 was published as a different document, and included three chapters discussing 1) definition, epidemiology, and pathogenesis; 2) clinical presentation and natural history and 3) diagnosis of EoE. The present work provides guidelines on the management of EoE in two final chapters: 4) treatment and 5) monitoring and follow-up, and also includes considerations on knowledge gaps and a proposed research agenda for the coming years. The guideline was developed through a Delphi process, with grading of the strength and quality of the evidence of the recommendations performed according to accepted GRADE criteria.This document has received the endorsement of three Italian national societies including the Italian Society of Gastroenterology (SIGE), the Italian Society of Neurogastroenterology and Motility (SINGEM), and the Italian Society of Allergology, Asthma, and Clinical Immunology (SIAAIC). The guidelines also involved the contribution of members of ESEO Italia, the Italian Association of Families Against EoE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Medical treatment of eosinophilic esophagitis.
- Author
-
Marshall, Hannah F. and Lee Qiyu, Melvin
- Subjects
- *
THERAPEUTICS , *EOSINOPHILIC esophagitis , *TREATMENT effectiveness , *REMISSION induction - Abstract
This article provides a summary of a Cochrane review on the medical treatment of eosinophilic esophagitis (EoE). EoE is a chronic inflammatory condition of the esophagus that can affect individuals of all ages, but is more common in males and adults. The review evaluated the efficacy and safety of different medical interventions for EoE, including corticosteroids and biologics. The findings suggest that corticosteroids improve clinical and histological outcomes, while biologics may improve clinical outcomes. However, the cost and availability of biologics should be considered. Further research and cost-effectiveness analyses are needed to fully evaluate and compare these treatments. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
6. The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis – Definition, Clinical Presentation and Diagnosis.
- Author
-
de Bortoli, Nicola, Visaggi, Pierfrancesco, Penagini, Roberto, Annibale, Bruno, Baiano Svizzero, Federica, Barbara, Giovanni, Bartolo, Ottavia, Battaglia, Edda, Di Sabatino, Antonio, De Angelis, Paola, Docimo, Ludovico, Frazzoni, Marzio, Furnari, Manuele, Iori, Andrea, Iovino, Paola, Lenti, Marco Vincenzo, Marabotto, Elisa, Marasco, Giovanni, Mauro, Aurelio, and Oliva, Salvatore
- Abstract
Eosinophilic esophagitis (EoE) is a chronic type 2-mediated inflammatory disease of the esophagus that represents the most common eosinophilic gastrointestinal disease. Experts in the field of EoE across Italy (i.e., EoETALY Consensus Group) including gastroenterologists, endoscopists, allergologists/immunologists, and paediatricians conducted a Delphi process to develop updated consensus statements for the management of patients with EoE and update the previous position paper of the Italian Society of Gastroenterology (SIGE) in light of recent evidence. Grading of the strength and quality of the evidence of the recommendations was performed using accepted GRADE criteria. The guideline is divided in two documents: Part 1 includes three chapters, namely 1) definition, epidemiology, and pathogenesis; 2) clinical presentation and natural history, and 3) diagnosis, while Part 2 includes two chapters: 4) treatment and 5) monitoring and follow-up. This document has received the endorsement of three Italian national societies including the SIGE, the Italian Society of Neurogastroenterology and Motility (SINGEM), and the Italian Society of Allergology, Asthma, and Clinical Immunology (SIAAIC). With regards to patients' involvement, these guidelines involved the contribution of members of ESEO Italia, the Italian Association of Families Against EoE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Overlap of eosinophilic esophagitis with inborn errors of immunity and immune dysregulation.
- Author
-
Constantine, Gregory M. and Khoury, Paneez
- Published
- 2024
- Full Text
- View/download PDF
8. Mepo for Eosinophilic Esophagitis (EoE) Study
- Author
-
GlaxoSmithKline, University of Utah, Northwestern University, and MNGI Digestive Health, P.A.
- Published
- 2023
9. Diagnosis and management of eosinophilic esophagitis and esophageal food impaction in adults: A position paper issued by the Austrian Society of Gastroenterology and Hepatology (ÖGGH)
- Author
-
Schlager, Hansjörg, Baumann-Durchschein, Franziska, Steidl, Karin, Häfner, Michael, Dinkhauser, Patrick, Weitersberger, Michael, Holzinger, Josef, Mader, Markus, Gröchenig, Hans Peter, Madl, Christian, and Schreiner, Philipp
- Published
- 2024
- Full Text
- View/download PDF
10. Vasoactive Intestinal Peptide Receptor, CRTH2, Antagonist Treatment Improves Eosinophil and Mast Cell-Mediated Esophageal Remodeling and Motility Dysfunction in Eosinophilic Esophagitis.
- Author
-
Yadavalli, Chandra Sekhar, Upparahalli Venkateshaiah, Sathisha, Verma, Alok K., Kathera, Chandrasekhar, Duncan, Pearce S., Vaezi, Michael, Paul, Richard J., and Mishra, Anil
- Subjects
- *
ESOPHAGEAL motility , *VASOACTIVE intestinal peptide , *EOSINOPHILIC esophagitis , *EOSINOPHILS , *MAST cells , *PEPTIDE receptors , *NASAL mucosa - Abstract
Background and Aims: Ultrasonography has shown that eosinophils accumulate in each segment of the esophageal mucosa in human EoE, ultimately promoting esophageal motility dysfunction; however, no mechanistic evidence explains how or why this accumulation occurs. Methods: Quantitative PCR, ELISA, flow cytometry, immunostaining, and immunofluorescence analyses were performed using antibodies specific to the related antigens and receptors. Results: In deep esophageal biopsies of EoE patients, eosinophils and mast cells accumulate adjacent to nerve cell-derived VIP in each esophageal segment. qRT-PCR analysis revealed five- to sixfold increases in expression levels of VIP, CRTH2, and VAPC2 receptors and proteins in human blood- and tissue-accumulated eosinophils and mast cells. We also observed a significant correlation between mRNA CRTH2 levels and eosinophil- and nerve cell-derived VIPs in human EoE (p < 0.05). We provide evidence that eosinophil and mast cell deficiency following CRTH2 antagonist treatment improves motility dysfunction in a chronic DOX-inducible CC10-IL-13 murine model of experimental EoE. Conclusions: CRTH2 antagonist treatment is a novel therapeutic strategy for inflammatory cell-induced esophageal motility dysfunction in IL-13-induced chronic experimental EoE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Systematic identification of genotype-dependent enhancer variants in eosinophilic esophagitis.
- Author
-
Shook, Molly S., Lu, Xiaoming, Chen, Xiaoting, Parameswaran, Sreeja, Edsall, Lee, Trimarchi, Michael P., Ernst, Kevin, Granitto, Marissa, Forney, Carmy, Donmez, Omer A., Diouf, Arame A., VonHandorf, Andrew, Rothenberg, Marc E., Weirauch, Matthew T., and Kottyan, Leah C.
- Subjects
- *
EOSINOPHILIC esophagitis , *LOCUS (Genetics) , *GENE expression , *GENETIC variation , *GENETIC regulation , *REPORTER genes - Abstract
Eosinophilic esophagitis (EoE) is a rare atopic disorder associated with esophageal dysfunction, including difficulty swallowing, food impaction, and inflammation, that develops in a small subset of people with food allergies. Genome-wide association studies (GWASs) have identified 9 independent EoE risk loci reaching genome-wide significance (p < 5 × 10−8) and 27 additional loci of suggestive significance (5 × 10−8 < p < 1 × 10−5). In the current study, we perform linkage disequilibrium (LD) expansion of these loci to nominate a set of 531 variants that are potentially causal. To systematically interrogate the gene regulatory activity of these variants, we designed a massively parallel reporter assay (MPRA) containing the alleles of each variant within their genomic sequence context cloned into a GFP reporter library. Analysis of reporter gene expression in TE-7, HaCaT, and Jurkat cells revealed cell-type-specific gene regulation. We identify 32 allelic enhancer variants, representing 6 genome-wide significant EoE loci and 7 suggestive EoE loci, that regulate reporter gene expression in a genotype-dependent manner in at least one cellular context. By annotating these variants with expression quantitative trait loci (eQTL) and chromatin looping data in related tissues and cell types, we identify putative target genes affected by genetic variation in individuals with EoE. Transcription factor enrichment analyses reveal possible roles for cell-type-specific regulators, including GATA3. Our approach reduces the large set of EoE-associated variants to a set of 32 with allelic regulatory activity, providing functional insights into the effects of genetic variation in this disease. [Display omitted] Shook et al. developed and applied a massively parallel reporter assay for the allergic disease eosinophilic esophagitis (EoE). They identified common polymorphisms associated with EoE risk that also impacted transcriptional regulation. This study is an important step toward understanding how EoE genetic risk variants lead to genotype-dependent biology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Real-World Efficacy of Dupilumab in Severe, Treatment-Refractory, and Fibrostenotic Patients With Eosinophilic Esophagitis.
- Author
-
Lee, Christopher J. and Dellon, Evan S.
- Abstract
Dupilumab is approved for treatment of eosinophilic esophagitis (EoE), but real-world data are lacking. We aimed to determine the real-world efficacy of dupilumab in patients with severe, treatment-refractory, and fibrostenotic EoE. We conducted a retrospective cohort study of EoE patients prescribed dupilumab and who were treatment-refractory to standard modalities. Patient demographics, clinical characteristics, EoE history, and procedural data (including the histologically worst, predupilumab, and postdupilumab endoscopies) were extracted from medical records. Symptomatic, endoscopic, and histologic responses were assessed for the worst and predupilumab endoscopies compared with the postdupilumab endoscopy. We identified 46 patients with refractory fibrostenotic EoE who were treated with dupilumab. Patients showed endoscopic, histologic, and symptomatic improvement on dupilumab compared with both the worst and the predupilumab esophagogastroduodenoscopies. The peak eosinophil counts decreased markedly, and postdupilumab histologic response rates were 80% and 57% for fewer than 15 eosinophils per high-power field and 6 or fewer eosinophils per high-power field, respectively, and the Endoscopic Reference Score decreased from 5.01 to 1.89 (P <.001 for all). Although the proportion of strictures was stable, there was a significant increase in the predilation esophageal diameter (from 13.9 to 16.0 mm; P <.001). Global symptom improvement was reported in 91% (P <.001). In this population of severe, refractory, and fibrostenotic EoE patients, most achieved histologic, endoscopic, and symptom improvement with a median of 6 months of dupilumab, and esophageal stricture diameter improved. Dupilumab has real-world efficacy for a severe EoE population, most of whom would not have qualified for prior clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Treatment of Pediatric Eosinophilic Esophagitis: Traditional and Novel Therapies.
- Author
-
Sharlin, Colby S., Mukkada, Vincent A., Putnam, Philip E., and Bolton, Scott M.
- Abstract
Purpose of Review: This review presents and summarizes the existing studies on the treatment goals and options for pediatric eosinophilic esophagitis utilizing rigorous peer-reviewed literature. Recent Findings: In addition to traditional treatments, emerging biologic therapies continue to evolve the approach to treating pediatric eosinophilic esophagitis. Well defined treatment goals will aid the continued development of new therapies. Further, innovative assessment tools have changed how the clinician is able to assess the effectiveness of therapies with a trend toward less invasive options. Summary: The management of pediatric eosinophilic esophagitis continues to evolve with the advent of both novel treatment options and assessment tools. Treatment choices, with benefits and risks involved, should be presented to families upon diagnosis and tailored towards the individual patient and likelihood of adherence and success. Biologic therapy for EoE presents an exciting option for both first line therapy and escalation for those with severe or unresponsive disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Bulk T‐cell receptor sequencing confirms clonality in pediatric eosinophilic esophagitis and identifies a food‐specific repertoire.
- Author
-
Janarthanam, Rethavathi, Kuang, Fei Li, Zalewski, Angelika, Amsden, Katie, Wang, Ming‐Yu, Ostilla, Lorena, Keeley, Kaitlyn, Hirano, Ikuo, Kagalwalla, Amir, Wershil, Barry K., Gonsalves, Nirmala, and Wechsler, Joshua B.
- Subjects
- *
EOSINOPHILIC esophagitis , *T cells , *ELIMINATION diets , *THERAPEUTICS , *ELEMENTAL diet - Abstract
Background: Eosinophilic esophagitis (EoE) involves a chronic immune‐mediated response to dietary antigens. Recent work identifies T‐cell clonality in children with EoE, however, it is unknown whether this is true in adults or whether there is a restricted food‐specific T‐cell repertoire. We sought to confirm T‐cell receptor (TCR) clonality in EoE and assess for differences with specific food triggers. Methods: Bulk TCR sequencing was performed on mRNA isolated from esophageal biopsies obtained from adults and children with EoE (n = 15) who had food triggers confirmed by endoscopic evaluation. Non‐EoE adult and pediatric controls (n = 10) were included. Differences in TCR clonality by disease and treatment status were assessed. Shared and similar V‐J‐CDR3s were assessed based on specific food triggers. Results: Active EoE biopsies from children but not adults displayed decreased unique TCRα/β clonotypes and increased relative abundance of TCRs comprising >1% of the total compared to non‐EoE controls and paired inactive EoE samples. Among patients in which baseline, post diet elimination, and food trigger reintroduction samples (n = 6) were obtained, we observed ~1% of TCRs were shared only between pre‐diet elimination and trigger reintroduction. Patients with a shared EoE trigger (milk) had a greater degree of shared and similar TCRs compared to patients with differing triggers (seafood, wheat, egg, soy). Conclusion: We confirmed relative clonality in children but not adults with active EoE and identified potential food‐specific TCRs, particularly for milk‐triggered EoE. Further studies are needed to better identify the broad TCR repertoire relevant to food triggers. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Food elimination diet is a viable alternative therapy for eosinophilic esophagitis responsive to proton pump inhibitors
- Author
-
Twan Sia, Evan Cunningham, Megan Miller, Rebecca Nitschelm, Riki Tanaka, Taylor Epstein, Kendall Garrett, Amy Huang, Daniel Pak, Ally Scheve, and John Leung
- Subjects
PPI ,FED ,Eosinophils ,EoE ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background First-line treatment of eosinophilic esophagitis (EoE) includes monotherapy with proton-pump inhibitors (PPIs), food elimination diet (FED), or topical corticosteroids. Current guidelines suggest patients with EoE should continue any responsive first-line monotherapies. However, the efficacy of FED monotherapy in patients with EoE responsive to PPI monotherapy has not been well studied. Our study aimed to investigate how attempting FED monotherapy after experiencing remission of EoE after PPI monotherapy influenced long-term EoE management. Methods We retrospectively identified patients with EoE responsive to PPI monotherapy who trialed FED monotherapy. We then employed a mixed method approach to a prospective cohort. Selected patients were observed long term for quantitative outcomes, while qualitative results were obtained from patient surveys regarding their perspectives on the trial of FED monotherapy. Results We identified 22 patients who trialed FED monotherapy after experiencing remission of EoE following PPI monotherapy. Of these 22 patients, 13 had remission of EoE with FED monotherapy, while 9 had re-activation of EoE. Out of 22 patients, 15 were enrolled in a cohort for observation. No exacerbations of EoE occurred while on maintenance treatment. Most patients stated that they would recommend this process to others with EoE (93.33%) and that trial of FED monotherapy helped them identify a treatment plan that aligned with their lifestyle (80%). Conclusion Our work shows that FED monotherapy can be an effective alternative for patients with EoE responsive to PPI monotherapy that may improve patient quality of life, suggesting alternative treatment options should be considered for monotherapy-responsive EoE.
- Published
- 2023
- Full Text
- View/download PDF
16. Vasoactive Intestinal Peptide Receptor, CRTH2, Antagonist Treatment Improves Eosinophil and Mast Cell-Mediated Esophageal Remodeling and Motility Dysfunction in Eosinophilic Esophagitis
- Author
-
Chandra Sekhar Yadavalli, Sathisha Upparahalli Venkateshaiah, Alok K. Verma, Chandrasekhar Kathera, Pearce S. Duncan, Michael Vaezi, Richard J. Paul, and Anil Mishra
- Subjects
CRTH2 ,eosinophils ,esophagus ,EoE ,mast cells ,motility ,Cytology ,QH573-671 - Abstract
Background and Aims: Ultrasonography has shown that eosinophils accumulate in each segment of the esophageal mucosa in human EoE, ultimately promoting esophageal motility dysfunction; however, no mechanistic evidence explains how or why this accumulation occurs. Methods: Quantitative PCR, ELISA, flow cytometry, immunostaining, and immunofluorescence analyses were performed using antibodies specific to the related antigens and receptors. Results: In deep esophageal biopsies of EoE patients, eosinophils and mast cells accumulate adjacent to nerve cell-derived VIP in each esophageal segment. qRT-PCR analysis revealed five- to sixfold increases in expression levels of VIP, CRTH2, and VAPC2 receptors and proteins in human blood- and tissue-accumulated eosinophils and mast cells. We also observed a significant correlation between mRNA CRTH2 levels and eosinophil- and nerve cell-derived VIPs in human EoE (p < 0.05). We provide evidence that eosinophil and mast cell deficiency following CRTH2 antagonist treatment improves motility dysfunction in a chronic DOX-inducible CC10-IL-13 murine model of experimental EoE. Conclusions: CRTH2 antagonist treatment is a novel therapeutic strategy for inflammatory cell-induced esophageal motility dysfunction in IL-13-induced chronic experimental EoE.
- Published
- 2024
- Full Text
- View/download PDF
17. Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge
- Author
-
Mayo Clinic, University of Cambridge, and CURED Foundation
- Published
- 2021
18. Exploring Treatment Options for Eosinophilic Esophagitis
- Author
-
Nicole Strossman, Katherine Donovan, Alexa Trovato, Nihita Manem, Nicole Nudelman, Micheal Tadros, and Christopher Ashley
- Subjects
eosinophilic esophagitis ,EoE ,elimination diet ,corticosteroids ,proton pump inhibitors ,dilation ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus, has been increasing in incidence over the past several years. Mainstays of treatment include dietary modifications, steroids, proton pump inhibitors (PPIs), and endoscopic dilation, with the goal being to control disease progression, promote remission, and alleviate symptoms, such as dysphagia and food impaction. In addition to these well-known treatment options, preliminary studies on new medications that target specific inflammatory mediators involved in the pathogenesis of EoE have shown promise in improving symptoms. This review article summarizes and discusses the application and efficacy of long-standing and promising new treatment options for EoE.
- Published
- 2022
- Full Text
- View/download PDF
19. Food elimination diet is a viable alternative therapy for eosinophilic esophagitis responsive to proton pump inhibitors.
- Author
-
Sia, Twan, Cunningham, Evan, Miller, Megan, Nitschelm, Rebecca, Tanaka, Riki, Epstein, Taylor, Garrett, Kendall, Huang, Amy, Pak, Daniel, Scheve, Ally, and Leung, John
- Subjects
- *
ELIMINATION diets , *EOSINOPHILIC esophagitis , *PROTON pump inhibitors - Abstract
Background: First-line treatment of eosinophilic esophagitis (EoE) includes monotherapy with proton-pump inhibitors (PPIs), food elimination diet (FED), or topical corticosteroids. Current guidelines suggest patients with EoE should continue any responsive first-line monotherapies. However, the efficacy of FED monotherapy in patients with EoE responsive to PPI monotherapy has not been well studied. Our study aimed to investigate how attempting FED monotherapy after experiencing remission of EoE after PPI monotherapy influenced long-term EoE management. Methods: We retrospectively identified patients with EoE responsive to PPI monotherapy who trialed FED monotherapy. We then employed a mixed method approach to a prospective cohort. Selected patients were observed long term for quantitative outcomes, while qualitative results were obtained from patient surveys regarding their perspectives on the trial of FED monotherapy. Results: We identified 22 patients who trialed FED monotherapy after experiencing remission of EoE following PPI monotherapy. Of these 22 patients, 13 had remission of EoE with FED monotherapy, while 9 had re-activation of EoE. Out of 22 patients, 15 were enrolled in a cohort for observation. No exacerbations of EoE occurred while on maintenance treatment. Most patients stated that they would recommend this process to others with EoE (93.33%) and that trial of FED monotherapy helped them identify a treatment plan that aligned with their lifestyle (80%). Conclusion: Our work shows that FED monotherapy can be an effective alternative for patients with EoE responsive to PPI monotherapy that may improve patient quality of life, suggesting alternative treatment options should be considered for monotherapy-responsive EoE. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Eosinophilic esophagitis is associated with increased risk of later inflammatory bowel disease in a nationwide Swedish population cohort
- Author
-
Uchida, Amiko M., Garber, John J., Pyne, Ashley, Peterson, Kathryn, Roelstraete, Bjorn, Olén, Ola, Halfvarson, Jonas, Ludvigsson, Jonas F., Uchida, Amiko M., Garber, John J., Pyne, Ashley, Peterson, Kathryn, Roelstraete, Bjorn, Olén, Ola, Halfvarson, Jonas, and Ludvigsson, Jonas F.
- Abstract
BACKGROUND: Earlier studies on the possible association between eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) have been contradictory. METHODS: Patients with biopsy-verified EoE diagnosed between 1990 and 2017 in Sweden (n = 1587) were age- and sex-matched with up to five general population reference individuals (n = 7808). EoE was defined using pathology reports from all 28 pathology centers in Sweden (the ESPRESSO study). Multivariate Cox regression then estimated hazard ratios for future IBD. IBD was defined based on the international classification of disease codes and histopathology codes. In secondary analyses, sibling comparators were used to further reduce potential familial confounding. Additionally, we performed logistic regression examining earlier IBD in EoE. RESULTS: During follow-up until 2020, 16 (0.01%) EoE patients and 21 (0.003%) general population reference individuals diagnosed with IBD, corresponding to a 3.5-fold increased risk of future IBD (aHR = 3.56; 95% CI 1.79-7.11). EoE was linked to Crohn's disease (aHR = 3.39 [95% CI 1.02-9.60]) but not to ulcerative colitis (aHR = 1.37; 95% CI 0.38-4.86). Compared to their siblings, patients with EoE were at a 2.48-fold increased risk of IBD (aHR = 2.48; 95% CI 0.92-6.70). Earlier IBD was 15 times more likely in EoE patients than in matched reference individuals (odds ratio, 15.39; 95% CI 7.68-33.59). CONCLUSION: In this nationwide cohort study, EoE was associated with a 3.5-fold increased risk of later IBD diagnosis. This risk increase may be due to shared genetic or early environmental risk factors, but also surveillance bias could play a role., AMU was supported by the Consortium of Eosinophilic GI Disease Researcher (CEGIR) Training Program. JFL was supported by Karolinska Institutet.
- Published
- 2024
- Full Text
- View/download PDF
21. Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions
- Author
-
Franciosi JP, Mougey EB, Dellon ES, Gutierrez-Junquera C, Fernandez-Fernandez S, Venkatesh RD, and Gupta SK
- Subjects
eosinophilic esophagitis ,eoe ,proton pump inhibitor medication ,ppi ,precision medicine ,Immunologic diseases. Allergy ,RC581-607 - Abstract
James P Franciosi,1,2 Edward B Mougey,3 Evan S Dellon,4 Carolina Gutierrez-Junquera,5 Sonia Fernandez-Fernandez,6 Rajitha D Venkatesh,7 Sandeep K Gupta8 1Division of Gastroenterology, Nemours Children’s Hospital, Orlando, FL, USA; 2College of Medicine, University of Central Florida, Orlando, FL, USA; 3Center for Pharmacogenomics and Translational Research, Nemours Children’s Health System, Jacksonville, FL, USA; 4Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA; 5Pediatric Gastroenterology Unit, Hospital Universitario Puerta de Hierro-Majadahonda, Autonomous University of Madrid, Madrid, Spain; 6Pediatric Gastroenterology Unit, Hospital Universitario Severo Ochoa, Madrid, Spain; 7Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Nationwide Children’s Hospital, Columbus, OH, USA; 8Section of Pediatric Gastroenterology, Hepatology and Nutrition, Riley Hospital for Children, Indiana University School of Medicine and Community Health Network, Indianapolis, IN, USACorrespondence: James P Franciosi, Division of Gastroenterology, Nemours Children’s Hospital, 6535 Nemours Parkway, Orlando, FL, 32827, USA, Tel +1 407 567 3832 ; +1 407 335 9908, Email james.franciosi@nemours.orgAbstract: Over the past decade, the role of proton pump inhibitor (PPI) medication has evolved from a diagnostic tool for Eosinophilic Esophagitis (EoE), by excluding patients with PPI responsive esophageal eosinophilia (PPI-REE), to a therapy for EoE. This transition resulted from the Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the Appraisal of Guidelines for Research and Evaluation II (AGREE) Conference to support PPI therapy for EoE in children and adults. Additional recent advances have suggested a role for genetic variations that might impact response to PPI therapy for EoE. This review article will explore a brief background of EoE, the evolution of PPI therapy for EoE and its proposed mechanisms, efficacy and safety in children and adults, and considerations for future PPI precision medicine in patients with EoE.Keywords: eosinophilic esophagitis, EoE, proton pump inhibitor medication, PPI, precision medicine
- Published
- 2022
22. Pathophysiology of Non-IgE-Mediated Food Allergy
- Author
-
Zhang S, Sicherer S, Berin MC, and Agyemang A
- Subjects
food protein-induced enterocolitis syndrome ,fpies ,food protein-induced enteropathy ,fpe ,food protein-induced allergic proctocolitis ,fpiap ,eosinophilic gastrointestinal disorders ,egids ,eosinophilic esophagitis ,eoe ,pathophysiology ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Shouling Zhang, Scott Sicherer, M Cecilia Berin, Amanda Agyemang Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, Kravis Children’s Hospital, The Elliot and Roslyn Jaffe Food Allergy Institute, New York, NY, USACorrespondence: Amanda AgyemangDepartment of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, Kravis Children’s Hospital, The Elliot and Roslyn Jaffe Food Allergy Institute, One Gustave L. Levy Place, Box 1198, New York, NY, 10029, USATel +212 241-5548Email amanda.agyemang@mountsinai.orgAbstract: Non-IgE-mediated food allergies are a group of disorders characterized by subacute or chronic inflammatory processes in the gut. Unlike IgE mediated food allergies that may result in multi-organ system anaphylaxis, the non-IgE mediated food allergies primarily affect the gastrointestinal tract. This review outlines the clinical manifestations, epidemiology, pathophysiology, and management of non-IgE-mediated food allergies. An updated literature search of selected non-IgE-mediated food allergies was conducted for this review using PubMed database to the current year (2021). Reviewed disorders include food protein-induced enterocolitis syndrome (FPIES), food-protein enteropathy (FPE), food protein-induced allergic proctocolitis (FPIAP), and eosinophilic gastrointestinal disorders (EGIDs) such as eosinophilic esophagitis (EoE). While extensive gains have been made in understanding FPIES, FPIAP, FPE, and EoE, more information is needed on the pathophysiology of these food allergies. Similarities among them include involvement of innate immunity, T-lymphocyte processes, alteration of the intestinal lumen at the cellular level with the appearance of inflammatory cells and associated histologic changes, and specific cytokine profiles suggesting food-specific, T-cell, and immune-mediated responses. While FPIES and FPIAP typically resolve in early childhood, EGIDs typically do not. Emerging new therapies for EoE offer promise of additional treatment options. Further studies identifying the immunopathogenesis, associated biomarkers, and mechanisms of tolerance are needed to inform prevention, diagnosis and management.Keywords: food protein-induced enterocolitis syndrome, FPIES, food protein-induced enteropathy, FPE, food protein-induced allergic proctocolitis, FPIAP, eosinophilic gastrointestinal disorders, EGIDs, eosinophilic esophagitis, EoE, pathophysiology
- Published
- 2021
23. Structured gastrointestinal pathology data acquisition and reporting: A strong foundation to improve care.
- Author
-
Farrell PR and Mezoff EA
- Subjects
- Humans, Gastroenterology organization & administration, Gastroenterology standards, Quality Improvement, Gastrointestinal Tract pathology, Gastrointestinal Diseases therapy, Gastrointestinal Diseases pathology
- Published
- 2024
- Full Text
- View/download PDF
24. Impact of Atopic Status on Clinical Presentation and Treatment Response in Pediatric Patients With Eosinophilic Esophagitis.
- Author
-
Kohley A, Attwal S, Jones SM, Akmyradov C, Chandler P, Tootle C, Nawaz S, Ayers T, Kawatu D, and Pesek RD
- Abstract
Background: Nearly 80% of patients with eosinophilic esophagitis (EoE) have coexisting atopic disease, yet a subset do not. It is unclear if this lack of atopy impacts presentation or response to therapy., Objectives: To characterize the presentation and response to therapy in atopic versus nonatopic pediatric patients with EoE., Methods: A case-control study of patients with EoE aged 6 months to 18 years (between 2018 and 2021) was performed. Patients were eligible if they had allergy testing, assessment of atopic history, and at least 1 endoscopy after initiation of treatment. Patients were considered nonatopic if they had negative allergy testing and no history of significant atopy. Response to therapy was classified as complete (peak eosinophils [eos] <15/high power field [hpf]), partial (≥15 eos/hpf but at least a 50% reduction in peak eos), or nonresponse., Results: A total of 168 participants were enrolled. The majority were White (n = 141, 84%), male (n = 124, 74%), and non-Hispanic (n = 158, 95%). The mean age at diagnosis was 9.4 years (standard deviation: ±4.8 years). A total of 123 participants (73.2%) were atopic, and 45 (26.8%) were nonatopic. There was no significant difference between atopic and nonatopic for most demographics or presenting symptoms. Nonatopic participants were younger than atopic participants (8.14 vs 9.8 years, P = .046). Swallowed topical corticosteroids (STC) and food elimination diets (FED) were used at a similar rate. There were no differences in treatment response between atopic/nonatopic participants in regard to STC, FED, or STC+FED., Conclusions: Atopic status does not significantly impact presentation or response to treatment in pediatric EoE, but a lack of atopy may be a risk for earlier onset of disease., (Copyright © 2024 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Author's reply: "The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis and the missing link: Helicobacter pylori infection".
- Author
-
de Bortoli N, Visaggi P, and Savarino EV
- Abstract
Competing Interests: Conflict of interest Nicola de Bortoli: Advisory board member for: AlfaSigma, Sanofi Genzyme, Dr.Falk; Lecture grants from Reckitt-Benkiser, Malesci, Dr. Flak, Sofar, Alfa-Sigma, Pharma-Line. Pierfrancesco Visaggi: Has served as speaker for Dr. Falk, JB Pharmaceuticals. Edoardo Vincenzo Savarino: has served as speaker for Abbvie, Agave, AGPharma, Alfasigma, Aurora Pharma, CaDiGroup, Celltrion, Dr Falk, EG Stada Group, Fenix Pharma, Fresenius Kabi, Galapagos, Janssen, JB Pharmaceuticals, Innovamedica/Adacyte, Malesci, Mayoly Biohealth, Omega Pharma, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Tillots, Unifarco; has served as consultant for Abbvie, Agave, Alfasigma, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Dr. Falk, Fenix Pharma, Fresenius Kabi, Janssen, JB Pharmaceuticals, Merck & Co, Nestlè, Reckitt Benckiser, Regeneron, Sanofi, SILA, Sofar, Synformulas GmbH, Takeda, Unifarco; he received research support from Pfizer, Reckitt Benckiser, SILA, Sofar, Unifarco, Zeta Farmaceutici.
- Published
- 2024
- Full Text
- View/download PDF
26. Eosinophilic Esophagitis
- Author
-
Li, Betty H., Gupta, Nina, Kavitt, Robert T., Patel, Dhyanesh A., editor, Kavitt, Robert T., editor, and Vaezi, Michael F., editor
- Published
- 2020
- Full Text
- View/download PDF
27. Prevalence of esophageal eosinophilia in patients referred for diagnostic upper gastrointestinal endoscopy
- Author
-
Nancy Abdel Fattah Ahmed, Hebat-Allah Moheb Amer, Dina Abdallah Ibrahim, and Islam Abd El-Hamid El-Zayyadi
- Subjects
EE ,EoE ,GERD ,Surgery ,RD1-811 ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background Several conditions are associated with esophageal eosinophilia such as eosinophilic esophagitis (EoE) and gastro-esophageal reflux disease (GERD). The aim of this study was to detect the prevalence of esophageal eosinophilia in patients with upper gastrointestinal (GI) symptoms referred for diagnostic upper GI endoscopy. This study included 86 patients who underwent upper GI endoscopy and biopsies. Results Esophageal eosinophilia EE was found in 26 patients (30.2%): 3 patients (3.5%) had EoE and 23 patients (26.7%) had low-grade esophageal eosinophilia. The most common presenting symptoms were heart burn in 84 patients (97.7%) and upper abdominal pain in 78 patients (90.7%). Reflux esophagitis (ERD) was observed in 18.6% of patients. In histopathological examination, EoE was found in 3.5%, mild reflux esophagitis in 37.2%, and severe reflux esophagitis in 16.3%. There is statistically significant correlation between EE and male sex, hypertension, dysphagia, hiatus hernia, incompetent cardia, and fixed rings. Age, incompetent cardia, and dysphagia were statistically significant independent predictors of low-grade EE. Conclusion Esophageal eosinophilia EE was found in 30.2% of patients: 3.5% had eosinophilic esophagitis EoE and 26.7% had low-grade esophageal eosinophilia.
- Published
- 2021
- Full Text
- View/download PDF
28. Œsophagite à éosinophiles : place de l'endoscopie.
- Author
-
Thobois, Maxime, Gomercic, Cécile, Piche, Thierry, and Vanbiervliet, Geoffroy
- Subjects
- *
PROTON pump inhibitors , *EOSINOPHILIC esophagitis , *MONOCLONAL antibodies , *DRUG therapy , *RARE diseases , *PATHOLOGY - Abstract
Résumé: Autrefois considérée comme une maladie rare, l'œsophagite à éosinophiles (EoE) suscite depuis une vingtaine d'années un intérêt croissant et est devenue l'une des affections les plus couramment diagnostiquées au cours de l'endoscopie digestive haute pour dysphagie chez l'enfant et l'adulte. La physiopathologie de cette affection est complexe et regroupe plusieurs mécanismes, notamment une réponse immunitaire anormale vis-à-vis d'antigènes environnementaux, une altération et fibrose de la muqueuse œsophagienne. Le diagnostic d'EoE est à la fois clinique avec dysfonction œsophagienne et histologique avec une infiltration de la muqueuse œsophagienne par les polynucléaires éosinophiles. L'arsenal thérapeutique pour traiter cette maladie est relativement large : règles hygiéno-diététiques, traitements pharmacologiques tels que les inhibiteurs de la pompe à protons et corticoïdes topiques, mais aussi les anticorps monoclonaux, en cours d'étude. L'endoscopie occupe également une place de choix dans la prise en charge thérapeutique avec une innocuité bien établie, notamment dans les formes fibro-sténosantes où l'efficacité des traitements pharmacologiques est souvent mise en défaut. Enfin, l'endoscopie a également un intérêt dans le suivi de la maladie avec un score de référence endoscopique « EREFS » (pour Exsudats, Anneaux, Œdèmes, Sillons et Sténoses) utilisé comme outil standardisé pour mieux évaluer et surveiller la maladie. Nous nous intéresserons ici particulièrement au rôle de l'endoscopie dans le diagnostic, le traitement et le suivi de l'EoE. Previously considered as a rare disease, eosinophilic esophagitis (EoE) has aroused growing interest over the past twenty years and has become one of the most currently diagnosed disease during upper digestive endoscopy in the context of dysphagia in children and adults. The pathophysiology of esophagitis is complex and involves several mechanisms, including, an abnormal immune response to environmental antigens, alteration of the esophageal mucosa, and the development of fibrosis. The diagnosis of EoE is both clinical with esophageal dysfunction and histological with infiltration of the esophageal mucosa by eosinophilic polynuclei. The therapeutic arsenal to treat this pathology is relatively broad and calls upon hygienic-dietary rules, pharmacological treatments such as proton pump inhibitors and topical corticoids, and also monoclonal antibodies currently under studies. Endoscopy also occupies an important role in therapeutic management, particularly in fibro-stenosing forms of EoE where the efficacy of pharmacological treatments is often challenged, with well-established safety. Finally, endoscopy also has an interest in the follow-up of the disease with an endoscopic reference score which is EREFS (exudates, rings, oedemas, furrows and stenoses) used as a standardized tool to better evaluate and monitor EoE. Here we will focus on the role of endoscopy in the diagnosis, treatment and follow-up of EoE. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Eosinophilic Esophagitis
- Author
-
Ghaffari, Gisoo, Craig, Tim, Section editor, Mahmoudi, Massoud, Section editor, Mahmoudi, Massoud, Editor-in-Chief, Ledford, Dennis K., Section Editor, and Craig, Timothy, Section Editor
- Published
- 2019
- Full Text
- View/download PDF
30. Development and technical validation of an artificial intelligence model for quantitative analysis of histopathologic features of eosinophilic esophagitis
- Author
-
Luisa Ricaurte Archila, Lindsey Smith, Hanna-Kaisa Sihvo, Thomas Westerling-Bui, Ville Koponen, Donnchadh M. O’Sullivan, Maria Camila Cardenas Fernandez, Erin E. Alexander, Yaohong Wang, Priyadharshini Sivasubramaniam, Ameya Patil, Puanani E. Hopson, Imad Absah, Karthik Ravi, Taofic Mounajjed, Rish Pai, Catherine Hagen, Christopher Hartley, Rondell P. Graham, and Roger K. Moreira
- Subjects
Artificial intelligence ,Digital pathology ,Eosinophilic esophagitis ,Deep learning ,EoE ,Eosinophils ,Computer applications to medicine. Medical informatics ,R858-859.7 ,Pathology ,RB1-214 - Abstract
Background: In an attempt to provide quantitative, reproducible, and standardized analyses in cases of eosinophilic esophagitis (EoE), we have developed an artificial intelligence (AI) digital pathology model for the evaluation of histologic features in the EoE/esophageal eosinophilia spectrum. Here, we describe the development and technical validation of this novel AI tool. Methods: A total of 10 726 objects and 56.2 mm2 of semantic segmentation areas were annotated on whole-slide images, utilizing a cloud-based, deep learning artificial intelligence platform (Aiforia Technologies, Helsinki, Finland). Our training set consisted of 40 carefully selected digitized esophageal biopsy slides which contained the full spectrum of changes typically seen in the setting of esophageal eosinophilia, ranging from normal mucosa to severe abnormalities with regard to each specific features included in our model. A subset of cases was reserved as independent “test sets” in order to assess the validity of the AI model outside the training set. Five specialized experienced gastrointestinal pathologists scored each feature blindly and independently of each other and of AI model results. Results: The performance of the AI model for all cell type features was similar/non-inferior to that of our group of GI pathologists (F1-scores: 94.5–94.8 for AI vs human and 92.6–96.0 for human vs human). Segmentation area features were rated for accuracy using the following scale: 1. “perfect or nearly perfect” (95%–100%, no significant errors), 2. “very good” (80%–95%, only minor errors), 3. “good” (70%–80%, significant errors but still captures the feature well), 4. “insufficient” (less than 70%, significant errors compromising feature recognition). Rating scores for tissue (1.01), spongiosis (1.15), basal layer (1.05), surface layer (1.04), lamina propria (1.15), and collagen (1.11) were in the “very good” to “perfect or nearly perfect” range, while degranulation (2.23) was rated between “good” and “very good”. Conclusion: Our newly developed AI-based tool showed an excellent performance (non-inferior to a group of experienced GI pathologists) for the recognition of various histologic features in the EoE/esophageal mucosal eosinophilia spectrum. This tool represents an important step in creating an accurate and reproducible method for semi-automated quantitative analysis to be used in the evaluation of esophageal biopsies in this clinical context.
- Published
- 2022
- Full Text
- View/download PDF
31. Viral Induced Effects on a Vulnerable Epithelium; Lessons Learned From Paediatric Asthma and Eosinophilic Oesophagitis.
- Author
-
Watkinson, Rebecca L., Looi, Kevin, Laing, Ingrid A., Cianferoni, Antonella, and Kicic, Anthony
- Subjects
EOSINOPHILIC esophagitis ,PEDIATRICS ,WHEEZE ,EPITHELIUM ,JUVENILE diseases ,BIOLOGICAL systems - Abstract
The epithelium is integral to the protection of many different biological systems and for the maintenance of biochemical homeostasis. Emerging evidence suggests that particular children have epithelial vulnerabilities leading to dysregulated barrier function and integrity, that resultantly contributes to disease pathogenesis. These epithelial vulnerabilities likely develop in utero or in early life due to various genetic, epigenetic and environmental factors. Although various epithelia are uniquely structured with specific function, prevalent allergic-type epithelial diseases in children potentially have common or parallel disease processes. These include inflammation and immune response dysregulation stemming from atypical epithelial barrier function and integrity. Two diseases where aetiology and pathogenesis are potentially linked to epithelial vulnerabilities include Paediatric Asthma and Eosinophilic Oesophagitis (EoE). For example, rhinovirus C (RV-C) is a known risk factor for paediatric asthma development and is known to disrupt respiratory epithelial barrier function causing acute inflammation. In addition, EoE, a prevalent atopic condition of the oesophageal epithelium, is characterised by similar innate immune and epithelial responses to viral injury. This review examines the current literature and identifies the gaps in the field defining viral-induced effects on a vulnerable respiratory epithelium and resulting chronic inflammation, drawing from knowledge generated in acute wheezing illness, paediatric asthma and EoE. Besides highlighting the importance of epithelial structure and barrier function in allergic disease pathogenesis regardless of specific epithelial sub-types, this review focuses on the importance of examining other parallel allergic-type disease processes that may uncover commonalities driving disease pathogenesis. This in turn may be beneficial in the development of common therapeutics for current clinical management and disease prevention in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Obesity reduces the requirement for subsequent esophageal stricture dilation in adults with eosinophilic esophagitis.
- Author
-
Miller, David, Mago, Sheena, Birk, John W., Dellon, Evan S., Feustel, Paul J., and Tadros, Micheal
- Abstract
Background: Eosinophilic esophagitis (EoE) causes esophageal narrowing and strictures, but factors that modify the severity of strictures and requirement for subsequent dilation are not well described. The aim of this study was to identify characteristics that impact the need for repeat (> 1) esophageal dilations in EoE patients. Methods: This was a single center retrospective cohort study over a 12-year period (September 2005–October 2017). Patients were identified using ICD9, ICD10, and CPT codes for esophageal dilation, eosinophilic esophagitis, and esophageal obstruction. Data for EoE clinical characteristics, treatments, and BMI were extracted and correlated to the number of esophageal dilations and time elapsed between dilations. Results: Of the 21 patients who met inclusion criteria, 11 (52%) had at least two dilations and 9 (43%) had three dilations. There was no differences baseline demographics between patients who needed ≥ 2 vs. those who needed one dilation. However, patients with a BMI > 30 had a significantly longer median time to second dilation compared to non-obese patients (4.9 years vs. 1.8 years; p = 0.027). Stratification by either high dose PPI or inhaled steroid use did not change this result. Conclusions: EoE patients with strictures who are obese have a reduced requirement for subsequent esophageal dilation. While the mechanism for this is not clear, increased attention of non-obese patients with fibrostenotic EoE is indicated as they are at higher risk for recurrent strictures. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
33. Patients with eosinophilic oesophagitis in Denmark have higher use of psychotropic drugs: A Danish nationwide study of psychotropic drug use in 3367 patients and 16,835 matched comparators.
- Author
-
Øvlisen AK, Frandsen LT, Hollænder M, Bredal K, Terkelsen JH, Kragholm KH, Torp-Pedersen C, Melgaard D, and Krarup AL
- Subjects
- Humans, Denmark epidemiology, Male, Female, Adult, Middle Aged, Incidence, Aged, Young Adult, Mental Disorders epidemiology, Mental Disorders drug therapy, Adolescent, Antidepressive Agents therapeutic use, Suicide, Attempted statistics & numerical data, Antipsychotic Agents therapeutic use, Case-Control Studies, Quality of Life, Eosinophilic Esophagitis epidemiology, Eosinophilic Esophagitis drug therapy, Psychotropic Drugs therapeutic use, Registries
- Abstract
Background: Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated disease of the oesophagus. Eosinophilic oesophagitis is associated with a substantial disease burden affecting the quality of life and affecting mental health. There are limited data describing the incidence of psychiatric disorders and the use of psychotropic drugs (PDs) in EoE patients., Objectives: The aim was to investigate whether EoE patients in Denmark have higher use of PDs, contacts with the department of psychiatry, and attempts of suicide or intentional self-harm compared with the general population after being diagnosed with EoE., Methods: This study was a nationwide, population-based register study including 3367 EoE patients and 16,835 age- and sex-matched comparators. A register-based EoE definition was used to identify cases. Incident PD use was extracted from the prescription register and information regarding psychiatric contacts was retrieved from the Danish Psychiatric Central Research Register., Results: The 5-year incidence of PD use in EoE patients was 13.8% compared to 7.1% of the matched comparators (Hazard ratio 1.83; confidence interval 1.6-2.0; p ≤ 0.001). Antidepressants were the most frequently prescribed PD, whereas antipsychotics were the least prescribed PD. Increasing age, lower educational level, and comorbidity (Charlson Comorbidity Index score ≥1) were associated with the prescription of PDs. The risk of PD use was lower in men than in women with EoE., Conclusion: Treatment with PDs were more common in EoE patients after they were diagnosed than in the general Danish population, indicating that EoE patients have an increased risk of psychiatric disorders., (© 2024 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)
- Published
- 2024
- Full Text
- View/download PDF
34. Manometric findings in children with eosinophilic esophagitis and persistent post-remission dysphagia.
- Author
-
Yogev D, Dorfman L, Mansi S, El-Chammas K, Lyles J, Mukkada V, and Kaul A
- Abstract
Objectives: Dysphagia is a frequent symptom of active eosinophilic esophagitis (EoE), but at times it persists despite attaining histologic healing and lack of fibro-stenotic changes. We aimed to describe the manometric findings in this subset of patients., Methods: A retrospective review of charts between 2013 and 2023 at a tertiary pediatric gastroenterology center, treating roughly 1500 EoE patients per year. We included children with EoE referred to high-resolution impedance manometry (HRIM) for persistent dysphagia despite histologic healing (i.e., <15 eosinophils/high-power field [Eos/hpf]). Data including initial EoE diagnosis, endoscopy reports, esophageal biopsies, treatment regimens, and HRIM were retrospectively collected., Results: The estimated prevalence of post-remission dysphagia in our cohort was exceedingly rare (<0.05%). Four patients met the eligibility criteria of histologic remission and absence of fibro-stenotic features on endoscopic evaluation and thus, were included in this case series. Patients achieved remission with steroids, proton-pump inhibitor, or both within a median time of 5 months from diagnosis. Peak Eosinophil count at remission was ≤5 Eos/hpf in three patients and ≤10 Eos/hpf in one. On HRIM, all four patients had a hypomotile esophagus and abnormal bolus clearance. Lower esophageal sphincter integrated relaxation pressure values were normal in three patients and elevated in one. Two patients were diagnosed with ineffective esophageal motility, one with aperistalsis and one with achalasia type 1., Conclusions: Post-remission dysphagia is rare in EoE. Esophageal dysmotility with a hypomotile pattern may contribute to the persistent dysphagia in children with EoE. HRIM should be considered in patients with EoE in whom symptoms persist despite histologic remission., Competing Interests: V. M. is consulting for Reneron, Shire/Takeda, and Sanofi. Adjudication board for Alladapt. The remaining authors declare no conflict of interest., (© 2024 The Author(s). JPGN Reports published by Wiley Periodicals LLC on behalf of The European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.)
- Published
- 2024
- Full Text
- View/download PDF
35. Tacrolimus (FK506) treatment protects allergen‐, IL‐5‐ and IL‐13‐induced mucosal eosinophilia.
- Author
-
Kandikattu, Hemanth Kumar, Venkateshaiah, Sathisha Upparahalli, Verma, Alok Kumar, and Mishra, Anil
- Subjects
- *
TACROLIMUS , *EOSINOPHILIA , *ELEMENTAL diet , *BASIC proteins , *PULMONARY fibrosis , *PULMONARY aspergillosis , *PULMONARY eosinophilia - Abstract
Summary: Eosinophils are a common clinical feature associated with chronic allergic diseases, and elemental diets, systemic steroids, anti‐IL‐5 and anti‐IL‐13 treatment have shown some therapeutic promise. Herein, we present evidence that pre‐ and post‐intraperitoneal administration of tacrolimus (FK506) is very effective in reducing CCR3/Siglec‐F+ eosinophils in Aspergillus‐challenged asthma and EoE, CD2‐IL‐5 induced global eosinophilia, and DOX regulated IL‐13‐induced asthma. We used flow cytometry and anti‐major basic protein (MBP) immunostaining to examine eosinophils in the spleen, bone marrow, BALF, lung, oesophagus and intestine. Additionally, we also performed ELISA and Western blot analyses to show that tacrolimus treatment also reduces the levels of eosinophil‐specific cytokines IL‐4, IL‐5, IL‐13 and TGF‐β, eosinophil‐specific chemokines Eotaxin‐1 and Eotaxin‐2, and progenitors of target RCAN1 mRNA and protein levels. Additionally, the current investigations also show that the TGF‐β‐mediated oesophageal and lung fibrosis is also reduced in Aspergillus‐challenged, CD2‐IL‐5 transgenic and DOX‐responsive IL‐13 mice. Mechanistically, we show that tacrolimus in vitro treatment inhibited bone marrow‐derived eosinophil proliferation and viability by promoting eosinophil apoptosis that may be associated with downregulation of RCAN1. Taken together, we provide in vivo and in vitro evidence that tacrolimus ameliorates eosinophil levels and associated pathogenesis in allergen‐, IL‐5‐ and IL‐13‐induced EoE, EG and asthma pathogenesis. Considering tacrolimus side‐effects and reactivity to several other drugs, we propose the topical use of tacrolimus for paediatric and low‐dose oral for adult patients as a novel therapeutic strategy for the clinical trial to reduce mucosal eosinophilia first in steroid‐refractory or elemental diet non‐responsive adult EoE, EG and asthma patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. Eozinofilní gastrointestinální onemocnění.
- Author
-
Frühauf, Pavel
- Abstract
Copyright of Pediatrie pro Praxi is the property of SOLEN sro and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
37. Poultry Meat allergy: a Review of Allergens and Clinical Phenotypes
- Author
-
Wanniang, Naphisabet, Codreanu-Morel, Françoise, Kuehn, Annette, and Morisset, Martine
- Published
- 2022
- Full Text
- View/download PDF
38. Eosinophilic esophagitis is associated with increased risk of later inflammatory bowel disease in a nationwide Swedish population cohort.
- Author
-
Uchida AM, Garber JJ, Pyne A, Peterson K, Roelstraete B, Olén O, Halfvarson J, and Ludvigsson JF
- Subjects
- Humans, Sweden epidemiology, Cohort Studies, Eosinophilic Esophagitis epidemiology, Inflammatory Bowel Diseases epidemiology, Crohn Disease diagnosis, Crohn Disease epidemiology
- Abstract
Background: Earlier studies on the possible association between eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) have been contradictory., Methods: Patients with biopsy-verified EoE diagnosed between 1990 and 2017 in Sweden (n = 1587) were age- and sex-matched with up to five general population reference individuals (n = 7808). EoE was defined using pathology reports from all 28 pathology centers in Sweden (the ESPRESSO study). Multivariate Cox regression then estimated hazard ratios for future IBD. IBD was defined based on the international classification of disease codes and histopathology codes. In secondary analyses, sibling comparators were used to further reduce potential familial confounding. Additionally, we performed logistic regression examining earlier IBD in EoE., Results: During follow-up until 2020, 16 (0.01%) EoE patients and 21 (0.003%) general population reference individuals diagnosed with IBD, corresponding to a 3.5-fold increased risk of future IBD (aHR = 3.56; 95% CI 1.79-7.11). EoE was linked to Crohn's disease (aHR = 3.39 [95% CI 1.02-9.60]) but not to ulcerative colitis (aHR = 1.37; 95% CI 0.38-4.86). Compared to their siblings, patients with EoE were at a 2.48-fold increased risk of IBD (aHR = 2.48; 95% CI 0.92-6.70). Earlier IBD was 15 times more likely in EoE patients than in matched reference individuals (odds ratio, 15.39; 95% CI 7.68-33.59)., Conclusion: In this nationwide cohort study, EoE was associated with a 3.5-fold increased risk of later IBD diagnosis. This risk increase may be due to shared genetic or early environmental risk factors, but also surveillance bias could play a role., (© 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)
- Published
- 2024
- Full Text
- View/download PDF
39. Poor Correlation of Oral Swabs with Esophageal Eosinophil Counts.
- Author
-
Avinashi, Vishal, Chan, Justin M., Bush, Jonathan W., Vallance, Bruce A., Yang, Hyungjun, Portales-Casamar, Elodie, Soller, Lianne, Mill, Christopher, and Chan, Edmond S.
- Abstract
Eosinophilic esophagitis (EoE) is a chronic condition that requires repeated endoscopies/biopsies to track the disease and treatment response. This invasive procedure involves risk to the patient and has significant costs. We studied whether the detection of specific proteins (cytokines and eosinophil degranulation products) from oral swabs could serve as a minimally invasive test for EoE. Swabs of the oral cavity (buccal and oropharyngeal) were obtained prior to endoscopy/biopsies in patients with EoE, possible EoE, and non-EoE patients in addition to obtaining additional esophageal biopsy tissue. ELISAs measuring the levels of cytokines IL-5, IL-8, IL-13, and eosinophil degranulation products including major basic protein (MBP), eosinophil derived neurotoxin (EDN), and eosinophil peroxidase (EPO) were performed on the samples. Comparisons were made to peak esophageal eosinophil counts. Tolerability of the swabs was evaluated. 43 patients, 4-17 years old, participated in the study. Swabs were well tolerated and all showed measurable protein. 26 patients had EoE [14 active (> 15 eosinophils/high power field), 12 non-active], 17 patients did not have EoE. Results obtained from oral swabs showed poor correlation with those from esophageal tissue. Only measurement of eosinophil degranulation products EDN and EPO from esophageal tissues showed strong correlations with eosinophil counts. In this study, the levels of cytokines and eosinophil degranulation products detected from oral swabs did not correlate with esophageal eosinophilia, and their detection would be insufficient to displace endoscopy/biopsies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
40. Health Service Use and Treatment Choices for Pediatric Eosinophilic Esophagitis: Findings From a Cross-Sectional Survey of Australian Carers
- Author
-
Nicole Hannan, Amie Steel, Sara S. McMillan, and Evelin Tiralongo
- Subjects
complementary medicine ,therapy ,allergy ,child ,EoE ,Pediatrics ,RJ1-570 - Abstract
Objectives: The incidence and the prevalence of eosinophilic esophagitis (EoE) are increasing, and healthcare utilization among children with EoE is high. This study provides novel insights into the health services and the treatments, including complementary medicines (CMs), used by carers to manage their children's EoE as well as the carers' beliefs and attitudes toward these treatments.Methods: A national cross-sectional online survey was conducted in Australia between September 2018 and February 2019. The survey included questions about health service and treatment utilization, health insurance and government support, health-related quality of life of children with EoE and their carers, views and attitudes toward CM use, and perceived efficacy of treatment.Results: The survey was completed by 181 carers (96.6% of whom were mothers) of EoE children. Most children (91.2%, n = 165) had seen a medical doctor for their EoE, and almost half had consulted with a CM practitioner (40.3%, n = 73). Pharmaceuticals (n = 156, 86.2%) were the most commonly used treatment option, followed by dietary changes (n = 142, 78.5%), CM products (n = 109, 60.2%), and CM therapies (n = 42, 23.2%). Most children received care from numerous practitioners on multiple occasions, indicating a substantial financial and treatment-related burden.Conclusions: A variety of practitioners are involved in the care of children with EoE, and a high rate of CM use warrants further attention to ensure that appropriate treatment is provided. Carer involvement and guidance, combined with individual practitioner expertise, referrals, and collaboration between providers, is essential to successfully navigate this complex disease and provide adequate care for these patients.
- Published
- 2020
- Full Text
- View/download PDF
41. Strategy for Food Reintroduction Following Empiric Elimination and Elemental Dietary Therapy in the Treatment of Eosinophilic Gastrointestinal Disorders.
- Author
-
Madison, Jill M., Bhardwaj, Vrinda, and Braskett, Melinda
- Abstract
Purpose of Review: This review presents the available data regarding efficacy of nutritional therapy, highlighting clinical decision points and a strategy for reintroduction of foods following an elemental diet for treatment of eosinophilic gastrointestinal disorders. Recent Findings: Elemental and empiric elimination diets are highly effective treatments for eosinophilic gastrointestinal diseases. Standardization in the reintroduction phase, after utilizing the diet for disease remission, is lacking. Summary: Clinicians are confronted with multiple challenges regarding the best practice for food reintroduction and identification of potential dietary triggers including order of foods being challenged and duration between endoscopic procedures. Individualization is required for preference and adherence to optimize quality of life and treatment success for this burdensome and life altering immune driven gastrointestinal disorder. Age specific concerns for children, teenagers, and adults should be assessed using a patient centric approach. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
42. Noncanonical NF-κB signaling and the essential kinase NIK modulate crucial features associated with eosinophilic esophagitis pathogenesis
- Author
-
Kristin Eden, Daniel E. Rothschild, Dylan K. McDaniel, Bettina Heid, and Irving C. Allen
- Subjects
EoE ,Eosinophils ,Inflammation ,TSLP ,Gastrointestinal ,NF-κB-inducing kinase ,Medicine ,Pathology ,RB1-214 - Abstract
Eosinophilic esophagitis (EoE) is an allergic disease of the esophagus driven by T cell and eosinophil responses to dietary allergens, resulting in chronic mucosal inflammation. Few spontaneous animal models of esophageal eosinophilia exist, with most studies relying on artificial sensitization procedures. NF-κB-inducing kinase (NIK; MAP3K14) is a key signaling molecule of the noncanonical NF-κB (NFKB1) pathway, an alternative signaling cascade producing chemokines involved in lymphoid stroma development and leukocyte trafficking. Nik−/− mice have been shown to develop a hypereosinophilic syndrome in peripheral blood and major filtering organs; however, the gastrointestinal mucosa of these mice has not been well characterized. We show that Nik−/− mice develop significant, localized eosinophilic esophagitis that mimics human EoE, including features such as severe eosinophil accumulation, degranulation, mucosal thickening, fibrosis and basal cell hyperplasia. The remainder of the GI tract, including the caudal stomach, small intestine and colon, in mice with active EoE are unaffected, also similar to human patients. Gene expression patterns in esophageal tissue of Nik−/− mice mimics human EoE, with thymic stromal lymphopoetin (TSLP) in particular also elevated at the protein level. In gene expression data sets from human biopsy specimens, we further show that many genes associated with noncanonical NF-κB signaling are significantly dysregulated in EoE patients, most notably a paradoxical upregulation of NIK itself with concurrent upregulation of powerful protein-level destabilizers of NIK. These findings suggest that Nik−/− mice could be useful as a spontaneous model of specific features of EoE and highlight a novel role for noncanonical NF-κB signaling in human patients.
- Published
- 2017
- Full Text
- View/download PDF
43. Performance of an Artificial Intelligence Model for Recognition and Quantitation of Histologic Features of Eosinophilic Esophagitis on Biopsy Samples.
- Author
-
Ricaurte Archila L, Smith L, Sihvo HK, Koponen V, Jenkins SM, O'Sullivan DM, Cardenas Fernandez MC, Wang Y, Sivasubramaniam P, Patil A, Hopson PE, Absah I, Ravi K, Mounajjed T, Dellon ES, Bredenoord AJ, Pai R, Hartley CP, Graham RP, and Moreira RK
- Abstract
We have developed an artificial intelligence (AI)-based digital pathology model for the evaluation of histologic features related to eosinophilic esophagitis (EoE). In this study, we evaluated the performance of our AI model in a cohort of pediatric and adult patients for histologic features included in the Eosinophilic Esophagitis Histologic Scoring System (EoEHSS). We collected a total of 203 esophageal biopsy samples from patients with mucosal eosinophilia of any degree (91 adult and 112 pediatric patients) and 10 normal controls from a prospectively maintained database. All cases were assessed by a specialized gastrointestinal (GI) pathologist for features in the EoEHSS at the time of original diagnosis and rescored by a central GI pathologist (R.K.M.). We subsequently analyzed whole-slide image digital slides using a supervised AI model operating in a cloud-based, deep learning AI platform (Aiforia Technologies) for peak eosinophil count (PEC) and several histopathologic features in the EoEHSS. The correlation and interobserver agreement between the AI model and pathologists (Pearson correlation coefficient [r
s ] = 0.89 and intraclass correlation coefficient [ICC] = 0.87 vs original pathologist; rs = 0.91 and ICC = 0.83 vs central pathologist) were similar to the correlation and interobserver agreement between pathologists for PEC (rs = 0.88 and ICC = 0.91) and broadly similar to those for most other histologic features in the EoEHSS. The AI model also accurately identified PEC of >15 eosinophils/high-power field by the original pathologist (area under the curve [AUC] = 0.98) and central pathologist (AUC = 0.98) and had similar AUCs for the presence of EoE-related endoscopic features to pathologists' assessment. Average eosinophils per epithelial unit area had similar performance compared to AI high-power field-based analysis. Our newly developed AI model can accurately identify, quantify, and score several of the main histopathologic features in the EoE spectrum, with agreement regarding EoEHSS scoring which was similar to that seen among GI pathologists., (Copyright © 2023. Published by Elsevier Inc.)- Published
- 2023
- Full Text
- View/download PDF
44. Outcome measures reported in randomised clinical trials for interventions in of mixed and non-IgE-mediated food allergy: a systematic review
- Author
-
Stikas, Charalampos Vlasios
- Subjects
non-IgE mediated ,food allergy ,systematic review ,Allergy and Immunology ,EoE ,Medicine and Health Sciences ,Medical Specialties - Abstract
This is a systematic review conducted as part of the Core Outcome Measures for Food Allergy (COMFA) project. It seeks to provide an updated overview of the outcomes reported in mixed and non-IgE-mediated food allergy randomised clinical trials
- Published
- 2023
- Full Text
- View/download PDF
45. Six-food elimination diet is less effective during pollen season in adults with eosinophilic esophagitis sensitized to pollens
- Author
-
Visaggi P., Savarino E., Del Corso G., Hunter H., Baiano Svizzero F., Till S. J., Jason D., Wong T., De Bortoli N., and Zeki S.
- Subjects
Biomedical statistics ,SFED ,Skin prick test ,Eosinophilic esophagitis ,EoE ,Pollen allergy - Abstract
The role of inhaled and swallowed aeroallergens in treatment outcomes of adult patients with eosinophilic esophagitis (EoE) is unclear. We hypothesized that the pollen season contributes to the failure of the 6-food elimination diet (SFED) in EoE. We compared outcomes of patients with EoE who underwent SFED during vs outside of the pollen season. Consecutive adult patients with EoE who underwent SFED and skin prick test (SPT) for birch and grass pollen were included. Individual pollen sensitization and pollen count data were analyzed to define whether each patient had been assessed during or outside of the pollen season after SFED. All patients had active EoE (>=15 eosinophils/high-power field) before SFED and adhered to the diet under the supervision of a dietitian. Fifty-eight patients were included, 62.0% had positive SPT for birch and/or grass, whereas 37.9% had negative SPT. Overall, SFED response was 56.9% (95% confidence interval, 44.1%-68.8%). When stratifying response according to whether the assessment had been performed during or outside of the pollen season, patients sensitized to pollens showed significantly lower response to SFED during compared with outside of the pollen season (21.4% vs 77.3%; P = 0.003). In addition, during the pollen season, patients with pollen sensitization had significantly lower response to SFED compared with those without sensitization (21.4% vs 77.8%; P = 0.01). Pollens may have a role in sustaining esophageal eosinophilia in sensitized adults with EoE despite avoidance of trigger foods. The SPT for pollens may identify patients less likely to respond to the diet during the pollen season.
- Published
- 2023
46. Esophageal IgE, IgG4, and mucosal eosinophilia in individuals with dysphagia.
- Author
-
Ramaswamy, Apoorva T., No, Jae Seong, Anderson, Lillye, Solomon, Aliza, Ciecierega, Thomas, Barfield, Elaine, Chien, Kimberly, Schnoll‐Sussman, Felice, and Reisacher, William R.
- Subjects
- *
FAILURE to thrive syndrome , *PEANUT allergy , *EOSINOPHILIA - Abstract
Background: Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, producing failure to thrive in infants and dysphagia with food impaction in older children and adults. Although most people with EoE manifest atopic/allergic disease, the specific allergens to which immunoglobulin E (IgE) is directed, if any, have not yet been characterized. Methods: Mucosal brush biopsy (MBB) and solid tissue biopsy (STB) specimens were prospectively obtained from 25 individuals with dysphagia and suspicion of EoE. Specific IgE (sIgE) against 112 epitopes from airborne and food proteins, antigens known to cause a polyclonal IgE response and IgG4 to food allergens, were measured. Results: There was no difference in total IgE harvested between the 2 biopsy methods (p > 0.05) or between the EoE‐positive (N = 12) and EoE‐negative (N = 13) groups (p > 0.05). None of the samples in either group contained measurable serum IgE to any of the airborne or food proteins tested, but low levels of IgE specific to Candida and Staphylococcus enterotoxins were detected. Low levels of IgG4 specific to wheat, soy, peanut, and egg were also detected. Conclusions: Both MBB and STB are able to harvest measureable levels of IgE and IgG4 from the esophageal mucosa. Low levels of serum‐specific IgE suggest that other inflammatory mechanisms, besides type I, IgE‐mediated, allergen‐specific hypersensitivity, may act as the primary catalyst for mucosal eosinophilia. Clarifying the role of both IgE‐mediated and non‒IgE‐mediated inflammatory mechanisms will help identify more targeted diagnostic and treatment strategies for individuals who present with dysphagia and esophageal eosinophilia. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
47. Elevated Tryptase in EoE Is an Independent Phenomenon Associated with Extra-Esophageal Symptoms.
- Author
-
Kutty, Geeta R., Downs-Kelly, Erinn, Crispin, Hilda T., and Peterson, Kathryn A.
- Subjects
- *
EOSINOPHILIC esophagitis , *URTICARIA , *TRYPTASE , *ATOPY , *REGRESSION analysis , *JOINT pain , *BIOCHEMISTRY , *HYDROLASES , *MAST cells , *PHENOMENOLOGY , *PROGNOSIS , *COMORBIDITY , *RETROSPECTIVE studies , *SEVERITY of illness index , *THERAPEUTICS - Abstract
Background: Eosinophilic esophagitis (EoE) is a chronic disease characterized histologically by > 15 eosinophils per high-power field (eos/hpf). Esophageal mucosal mast cells have been implicated in EoE pathogenesis. The association of atopy with EoE has been established but has not been correlated with levels of serum tryptase. The lack of concurrent atopy in some patients suggests the possibility that atopy may either be the related subtype of EoE or may be a sign of comorbidities. No study has looked at whether patients present with different phenotypes/comorbid disease when they have evidence of elevated serum tryptase. We hypothesized that these patients differ with respect to presentation and comorbidities with more refractory GI disease.Aims: To examine whether elevations of serum tryptase associate with different, more severe clinical presentations in EoE patients which may be explained via mast cell activation.Materials and Methods: Retrospective chart review identified 72 patients with EoE with results for serum tryptase between 2015 and 2016. Patients were classified as TryptaseHI (tryptase > 10.9 µg/l) and TryptaseLO (< 10.9 µg/l). Clinical characteristics and treatment response were compared using univariate analysis and multivariate regression between the groups.Results: Out of 72 patients, 12 were tested as TryptaseHI (16.7%, 95% CI 8.1-25.3%). TryptaseHI was associated frequently with asthma (P = 0.0003), urticaria (P = 0.002), arthralgia (P = 0.005), sinusitis (P = 0.03), nausea/vomiting (P = 0.046), and eosinophilic gastrointestinal disease (P = 0.001). Asthma and arthralgia were found to be significantly associated with TryptaseHI (P = 0.0013, P = 0.0098, respectively). Mucosal eosinophil counts and tryptase levels were not correlated (R2 0.095, P = 0.77). Tryptase did not resolve with resolution of esophageal eosinophilia.Conclusions: We found that EoE patients with elevated tryptase levels more commonly presented with asthma, urticaria, arthralgia, nausea/vomiting, sinusitis, and more distal eosinophilia. This indicates that atopy in EoE patients warrants further exploration. The lack of correlation between histologic remission and reduction of serum tryptase levels post-treatment suggests that mast cell activation may be an independent, yet associated disease. More study into this unique association is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
48. In Search of Biomarkers in Eosinophilic Oesophagitis: We are not There Yet!
- Author
-
Neeti Bhardwaj and Gisoo Ghaffari
- Subjects
eosinophilic oesophagitis ,biomarkers ,eotaxin-3 ,microrna ,mirna ,eoe ,mast cell ,mc ,cytokines ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Background: Eosiniphilic oesophagitis (EoE) is an immune-mediated disease with a complex pathophysiology. The accepted standard for objectively monitoring inflammation associated with this disorder is the number of eosinophils in oesophageal tissue biopsies obtained endoscopically. There is a need for alternative biomarkers that effectively correlate with disease activity and can hopefully be obtained non-invasively. The aim of this study is to review the literature on various biomarkers of EoE, with respect to their correlation to disease activity and response to treatment. Methods: A literature search was performed using PubMed and OVID with keyword combinations of EoE and various potential biomarkers. Between 2006 and 2015, 39 studies that investigated the correlation of various tissue and serum biomarkers with EoE disease were identified. Results: A number of candidates have emerged as potential biomarkers of inflammation in EoE. Eotaxin-3, interleukin (IL)-5, IL-13, microRNAs, and mast cell mediators have shown the most promise. Studies on these markers are quite heterogeneous in terms of methodology, with use of invasively as well as non-invasively obtained specimens. Conclusion: The quest for an ideal biomarker for EoE continues. Establishment of normal values, effects of concomitant atopic diseases, age and gender, and validation of methodology of the tests are some of the challenges that future research should address.
- Published
- 2016
49. Treatment Options in Eosinophilic Oesophagitis
- Author
-
Anna M. Lipowska, Robert T. Kavitt, and Michael F. Vaezi
- Subjects
eosinophilic oesophagitis ,eoe ,proton pump inhibitors ,ppi ,endoscopy ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Eosinophilic oesophagitis (EoE) is an increasingly prevalent chronic inflammatory disorder diagnosed by the presence of oesophageal symptoms and eosinophilic inflammation on endoscopic histology. Treatment of EoE centres around the ‘3 D’s’: drugs, diet, and dilation, which aim to both improve symptoms and prevent potential complications. Potential pharmacologic therapies include acid suppressing agents and corticosteroids, among others. Dietary strategies comprise the elemental diet, the empiric elimination diet, and the allergy testing-directed elimination diet. The therapeutic landscape of EoE is rapidly changing as our understanding of the disease evolves. This review aims to provide a comprehensive discussion of existing EoE therapies and to outline an approach to EoE management.
- Published
- 2016
50. Examining Disparities in Pediatric Eosinophilic Esophagitis.
- Author
-
Mehta P, Pan Z, Zhou W, Burger C, Menard-Katcher C, Bailey DD, and Furuta GT
- Subjects
- Child, Humans, Infant, Newborn, Infant, Child, Preschool, Adolescent, Retrospective Studies, Endoscopy, Ethnicity, Eosinophilic Esophagitis diagnosis, Eosinophilic Esophagitis epidemiology, Eosinophilic Esophagitis therapy
- Abstract
Background: Little is known regarding the impact of race, ethnicity, and socioeconomic status on the health outcomes of children with eosinophilic esophagitis (EoE)., Objective: To (1) identify demographic characteristics of children diagnosed with EoE in a large tertiary care center, and (2) determine associations between a patient's demographics and depth of evaluation or treatment choices., Methods: This retrospective cohort study included children 0 to 18 years old seen in Children's Hospital Colorado between January 1, 2009, and December 31, 2020. Demographics were extracted from the electronic medical record. Rural-Urban Commuting Area taxonomy codes were used to classify urbanization. Area Deprivation Index (ADI) scores were used to categorize neighborhood advantage/disadvantage. Data were analyzed using descriptive statistics and regression analysis., Results: The study included 2,117 children with EoE. Children with higher state ADI scores (greater neighborhood disadvantage) had less radiographic evaluation of their disease (odds ratio [95% CI] per unit increase in state ADI = 0.93 [0.89-0.97]; P = .0002) and had esophageal dilations at younger ages (r = -0.24; P = .007). Black children compared with White children were younger at diagnosis (8.3 y vs 10.0 y; P = .002). Children from rural areas were seen less by feeding therapy (3.9% vs 9.9%; P = .02), but were younger at their visits (2.3 y vs 4.3 y; P < .001)., Conclusions: In this study of children with EoE cared for in a large tertiary care center, we found differences in presentation and care depending on race, urbanization, and socioeconomic status., (Copyright © 2023 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.